Experts and Doctors on antineoplastic agents in Berlin, Germany

Summary

Locale: Berlin, Germany
Topic: antineoplastic agents

Top Publications

  1. Preissner S, Dunkel M, Hoffmann M, Preissner S, Genov N, Rong W, et al. Drug cocktail optimization in chemotherapy of cancer. PLoS ONE. 2012;7:e51020 pubmed publisher
    ..g. antiemetics or antibiotics is a preferred subject to improvement. A webtool, which allows drug cocktail optimization was developed and is publicly available on http://bioinformatics.charite.de/chemotherapy. ..
  2. Zietsch J, Ziegenhagen N, Heppner F, Reuss D, von Deimling A, Holtkamp N. The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. PLoS ONE. 2010;5:e11858 pubmed publisher
    ..Sunitinib is a drug targeting receptor tyrosine kinases (RTK) like PDGFRalpha, c-Kit and VEGFR-2. These genes are structurally related and cluster on chromosomal segment 4q12...
  3. Braumann C, Guenther N, Pohlenz J, Pfirrmann R, Menenakos C. Wound healing is not impaired in rats undergoing perioperative treatment with the antineoplastic agent taurolidine. Eur Surg Res. 2009;42:91-6 pubmed publisher
    ..No animal died. No relevant impairment of wound healing was observed independent of the different treatment strategies. Our results suggest that wound healing does not seem to be impaired by TRD in rats. ..
  4. Kiewe P, Seyfert S, Körper S, Rieger K, Thiel E, Knauf W. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma. 2003;44:1815-8 pubmed
    ..The question remains whether serologic screening for JC virus in patients with chronic lymphoproliferative disease undergoing intense chemotherapy might be valuable once sufficient antiviral treatment has been established. ..
  5. Albuschat R, Löwe W, Weber M, Luger P, Jendrossek V. 4-Anilinoquinazolines with Lavendustin A subunit as inhibitors of epidermal growth factor receptor tyrosine kinase: syntheses, chemical and pharmacological properties. Eur J Med Chem. 2004;39:1001-11 pubmed
    ..However, due to their instability 11a and 11b could not be obtained in a pure form. ..
  6. Kurbanov B, Geilen C, Fecker L, Orfanos C, Eberle J. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol. 2005;125:1010-9 pubmed
    ..Thus, DR4 expression in vivo and the high efficiency of DR4-mediated apoptosis may suggest reassessment of the suitability of TRAIL and especially of DR4-based strategies for melanoma treatment. ..
  7. Kim T, Schwarz M, Nogai H, Grille P, Westermann J, Plockinger U, et al. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20:1209-14 pubmed publisher
    ..Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine kinase inhibitors (TKIs), like sunitinib. The aim of this study was to investigate the effect of second-generation TKIs on thyroid function...
  8. Gluck S, von Minckwitz G, Untch M. Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. Breast. 2013;22:142-149 pubmed publisher
    ..To provide evidence-based treatment guidance, future clinical trials should include more patients over the age of 65 years. ..
  9. Schmidt C, Przybylski G. What can we learn from leukemia as for the process of lineage commitment in hematopoiesis?. Int Rev Immunol. 2001;20:107-15 pubmed
    ..Subsequently, myeloid or lymphoid markers are downregulated and the hematopoietic cell enters either myeloid, T-lymphoid or B-lymphoid differentiation pathway. ..

More Information

Publications189 found, 100 shown here

  1. Marnitz S, Köhler C, Füller J, Hinkelbein W, Schneider A. Uterus necrosis after radiochemotherapy in two patients with advanced cervical cancer. Strahlenther Onkol. 2006;182:45-51 pubmed
    ..Laparoscopy is an ideal technique to exclude or confirm this diagnosis. ..
  2. Lösler S, Schlief S, Kneifel C, Thiel E, Schrezenmeier H, Rojewski M. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system. Ann Hematol. 2009;88:1047-58 pubmed publisher
    ..The ability of modulators of the cellular redox system in clinically applicable concentrations to enhance the apoptotic effects of the two oxides in a synergistic way may be helpful to reduce their toxicity by optimizing their dose. ..
  3. Teichgraber U, Nagel S, Kausche S, Streitparth F, Cho C. Double-lumen central venous port catheters: simultaneous application for chemotherapy and parenteral nutrition in cancer patients. J Vasc Access. 2010;11:335-41 pubmed
    ..Potential advantages, complications, and the durations of simultaneous and single use of the catheter were assessed...
  4. Bertz J, Zang C, Liu H, Wächter M, Possinger K, Koeffler H, et al. Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib. Leuk Res. 2009;33:686-92 pubmed publisher
    ..Overall, our data suggest that the PPAR alpha/gamma ligands may have potentials in the treatment of CML in an adjuvant setting either before or after the development of imatinib resistance. ..
  5. Hellmann Regen J, Gertz K, Uhlemann R, Colla M, Endres M, Kronenberg G. Retinoic acid as target for local pharmacokinetic interaction with modafinil in neural cells. Eur Arch Psychiatry Clin Neurosci. 2012;262:697-704 pubmed publisher
    ..These kinds of drug effects may become highly relevant especially in the context of biomolecules such as RA whose local metabolism in brain is under tight spatial and temporal control. ..
  6. Britsch S, Li L, Kirchhoff S, Theuring F, Brinkmann V, Birchmeier C, et al. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 1998;12:1825-36 pubmed
    ..Together with previous observations, these findings establish the neuregulin signaling system as a key regulator in the development of neural crest cells. ..
  7. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M, et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018-36 pubmed publisher
    ..Metastasis formation in colon cancer severely reduces the survival rate in patients. S100A4, a calcium-binding protein, is implicated in promoting metastasis formation in colon cancer...
  8. Penack O, Thiel E, Notter M. Mast cell leukaemia. Br J Haematol. 2005;131:416 pubmed
  9. Bobrich E, Braumann C, Opitz I, Menenakos C, Kristiansen G, Jacobi C. Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy. J Surg Res. 2007;137:75-82 pubmed
    ..However, the biological behavior of this molecule is multivariant, controversial and still unclear. Further studies should elucidate its role in the epithelial tumor genesis. ..
  10. Stein U, Fleuter C, Siegel F, Smith J, Kopacek A, Scudiero D, et al. Impact of mutant ?-catenin on ABCB1 expression and therapy response in colon cancer cells. Br J Cancer. 2012;106:1395-405 pubmed publisher
    ..In patient samples, the same ?-catenin mutation was detected. The functional significance of the mutation for predicting patients' therapy response or for individualisation of chemotherapy regimens remains to be established. ..
  11. Reich G, Cornely O, Sandherr M, Kubin T, Krause S, Einsele H, et al. Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol. 2005;130:265-70 pubmed
    ..One patient (0.4%) died from infection. Empirical first-line therapy with MPM as well as with P/T is safe and effective in febrile episodes emerging after ASCT. Higher response rates to primary treatment can be achieved with MPM. ..
  12. Braumann C, Tangermann J, Jacobi C, Muller J, Dubiel W. Novel anti-angiogenic compounds for application in tumor therapy - COP9 signalosome-associated kinases as possible targets. Mini Rev Med Chem. 2008;8:421-8 pubmed
    ..Whereas curcumin and emodin can act via inhibition of COP9 signalosome-associated kinases, taurolidine blocks protein biosynthesis. ..
  13. Chahoud I, Paumgartten F. Dose-response relationships of rat fetal skeleton variations: Relevance for risk assessment. Environ Res. 2009;109:922-9 pubmed publisher
  14. Bachran C, Weng A, Bachran D, Riese S, Schellmann N, Melzig M, et al. The distribution of saponins in vivo affects their synergy with chimeric toxins against tumours expressing human epidermal growth factor receptors in mice. Br J Pharmacol. 2010;159:345-52 pubmed publisher
    ..c. injection, and antitumour synergy with chimeric toxins was correlated with the removal of excess Spn from tissues. Disposition of Spn in vivo may critically determine antitumour synergy with chimeric toxins. ..
  15. Pavel M, Kidd M, Modlin I. Systemic therapeutic options for carcinoid. Semin Oncol. 2013;40:84-99 pubmed publisher
    ..Increased efficacy requires a better understanding of the underlying tumor biology and identification of molecular pathological criteria to allow appropriate preselection of candidates for targeted therapies. ..
  16. Assaf C. Denileukin diftitox therapy for patients with tumour-stage mycosis fungoides. Dermatol Clin. 2008;26 Suppl 1:21-2 pubmed
  17. Wenzel J, Zeisig R, Fichtner I. Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. Int J Pharm. 2009;370:121-8 pubmed publisher
  18. Grohmann M, Paulmann N, Fleischhauer S, Vowinckel J, Priller J, Walther D. A mammalianized synthetic nitroreductase gene for high-level expression. BMC Cancer. 2009;9:301 pubmed publisher
    ..Our results show that codon optimization overcomes expression limitations of the bacterial ntr gene in mammalian cells, thereby improving the NTR/CB1954 system at translational level for cancer gene therapy in humans. ..
  19. Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, et al. Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-alpha treatment in patients with malignant melanoma: results from the multicenter DeCOG trial. J Immunother. 2010;33:106-14 pubmed publisher
    ..A higher pretreatment depression score was found to be a risk factor for an early drop-out during therapy. Pretreatment screening and an interdisciplinary care of the patients is recommended. ..
  20. Dörffel Y, Swidsinski A, Loening Baucke V, Wiedenmann B, Pavel M. Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohn's disease and the effect of therapy. Inflamm Bowel Dis. 2012;18:1663-71 pubmed publisher
    ..Patients with NET and CD show similarities in their abnormalities of the fecal biostructure. Interferon alpha and systemic chemotherapy significantly improved the fecal biostructure in patients with midgut NET. ..
  21. Klotz M, Schmid E, Steiner Hahn K, Rose T, Laube J, Roese L, et al. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY-853474. Biomarkers. 2012;17:325-35 pubmed publisher
    ..IHC-based analysis of target phosphorylation in tumor biopsies is recommended in addition to testing plasma biomarkers for response monitoring. ..
  22. Lücking U, Jautelat R, Krüger M, Brumby T, Lienau P, Schafer M, et al. The lab oddity prevails: discovery of pan-CDK inhibitor (R)-S-cyclopropyl-S-(4-{[4-{[(1R,2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide (BAY 1000394) for the treatment of cancer. ChemMedChem. 2013;8:1067-85 pubmed publisher
  23. Hopfner M, Sutter A, Gerst B, Zeitz M, Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer. 2003;89:1766-75 pubmed
    ..Thus, EGFR-TK inhibition appears to be a promising novel approach for the treatment of NE tumour disease. ..
  24. Sturm I, Bosanquet A, Hummel M, Dorken B, Daniel P. In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis. BMC Cancer. 2005;5:105 pubmed
    ..These data indicate that polymorphic variants of p53 codon 72 are not clinically relevant for apoptosis induction or patient survival in B-CLL. ..
  25. Oertel S, Verschuuren E, Reinke P, Zeidler K, Papp Vary M, Babel N, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant. 2005;5:2901-6 pubmed
    ..Two patients relapsed, at intervals 3 and 5 months after obtaining complete remission. Rituximab proved to be well tolerated and effective in the treatment of PTLD. ..
  26. Chekerov R, Denkert C, Boehmer D, Suesse A, Widing A, Ruhmland B, et al. Online tumor conference in the clinical management of gynecological cancer: experience from a pilot study in Germany. Int J Gynecol Cancer. 2008;18:1-7 pubmed
    ..In conclusion, the online tumor conference is feasible and represents a time-saving possibility for gynecological oncologist to receive a treatment recommendation based on the best available clinical and scientific evidence. ..
  27. Czabanka M, Korherr C, Brinkmann U, Vajkoczy P. Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. Front Biosci. 2008;13:7243-9 pubmed
    ..The TBK-1 pathway might be an important cross-link between angiogenesis and inflammation representing a possible target for anti-tumor therapy. ..
  28. Wiedenmann B, Pavel M, Kos Kudla B. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors. Neuroendocrinology. 2011;94:177-90 pubmed publisher
    ..Here we review potential molecular targets in pancreatic NET and summarize the available data for targeted agents from phase II and III trials open to patients with this tumor. ..
  29. Bernasconi E, Gaudio E, Lejeune P, Tarantelli C, Cascione L, Kwee I, et al. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. Br J Haematol. 2017;178:936-948 pubmed publisher
    ..Our data also indicate the use of combination schemes targeting EZH2, mTOR and BTK alongside BET bromodomains. ..
  30. Roigas J, Wallen E, Loening S, Moseley P. Estramustine phosphate enhances the effects of hyperthermia and induces the small heat shock protein HSP27 in the human prostate carcinoma cell line PC-3. Urol Res. 2002;30:130-5 pubmed
    ..Our data show that EMP sensitizes PC-3 cells to hyperthermia induced cytotoxicity. This observation supports the rationale for multimodal treatment approaches in locally advanced prostate cancer. ..
  31. Reimer T, Anagnostopoulos I, Erdmann B, Lehmann I, Stein H, Daniel P, et al. Reevaluation of the 22-1-1 antibody and its putative antigen, EBAG9/RCAS1, as a tumor marker. BMC Cancer. 2005;5:47 pubmed
    ..We suggest that the estrogen-inducible EBAG9 gene-product and the 22-1-1 defined antigen are structurally and functionally separate antigens. ..
  32. Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim). 2007;340:117-26 pubmed
    ..This review covers some relevant examples of preclinical and clinical research on novel non platinum metal complexes. ..
  33. Loddenkemper K, Hoyer B, Loddenkemper C, Hermann K, Rogalla P, Forster G, et al. A case of Erdheim-Chester disease initially mistaken for Ormond's disease. Nat Clin Pract Rheumatol. 2008;4:50-5 pubmed publisher
    ..Erdheim-Chester disease with retroperitoneal fibrosis and bone sclerosis. Treatment with glucocorticoids failed. The patient's symptoms improved significantly after initiation of interferon-alpha therapy. ..
  34. Penack O, Rempf P, Graf B, Blau I, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol. 2008;19:984-9 pubmed publisher
    ..Our data also show that GEI testing in BAL can be useful for early diagnosis of IA in patients with hematological malignancies and pulmonary infiltrates. ..
  35. Eschenburg G, Eggert A, Schramm A, Lode H, Hundsdoerfer P. Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-?-independent apoptosis. Cancer Res. 2012;72:2645-56 pubmed publisher
    ..Together, our findings show that XIAP targeting sensitizes neuroblastoma to chemotherapy-induced apoptosis, suggesting a novel therapeutic approach to treat this childhood malignancy. ..
  36. Paz Ares L, Hirsh V, Zhang L, De Marinis F, Yang J, Wakelee H, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung. J Thorac Oncol. 2015;10:1745-53 pubmed publisher
    ..Third-/fourth-line sorafenib therapy did not significantly increase OS in patients with relapsed/refractory NSCLC, despite significantly increasing PFS. ..
  37. Lichtner R, Menrad A, Sommer A, Klar U, Schneider M. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res. 2001;61:5790-5 pubmed
    ..This novel mode of action of quinazoline tyrosine kinase inhibitors may be the basis for their extraordinary potency especially in conditions when the ligand is present in limiting amounts. ..
  38. Materna V, Liedert B, Thomale J, Lage H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer. 2005;115:393-402 pubmed
    ..This was reflected by the specific inhibition of MRP2 by ribozyme technology, indicating that this gene therapeutic approach may be applicable as a specific means to overcome platinum resistance in human neoplasms. ..
  39. Krawtchenko N, Roewert Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157 Suppl 2:34-40 pubmed
    ..0001). Imiquimod treatment of AK resulted in superior sustained clearance and cosmetic outcomes compared with cryosurgery and 5-FU. It should be considered as a first line therapy for sustained treatment of AK. ..
  40. Fuchs H, Bachran D, Panjideh H, Schellmann N, Weng A, Melzig M, et al. Saponins as tool for improved targeted tumor therapies. Curr Drug Targets. 2009;10:140-51 pubmed
  41. von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, et al. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Exp Cell Res. 2009;315:2471-8 pubmed publisher
  42. Dudeck O, Zeile M, Reichardt P, Pink D. Comparison of RECIST and Choi criteria for computed tomographic response evaluation in patients with advanced gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2011;22:1828-33 pubmed publisher
    ..Controversies exist about computed tomography (CT) response evaluation criteria for patients with gastrointestinal stromal tumor (GIST)...
  43. Jehn C, Böning L, Kroning H, Possinger K, Luftner D. Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer. 2012;106:274-8 pubmed publisher
    ..53-0.87; P=0.0019). This NIS reports one of the largest mCRC collectives >65 years and reduced performance status. Cetuximab has a similar efficacy and safety profile for pts aged ? 65 and >65 years. ..
  44. Fecker L, Eberle J, Orfanos C, Geilen C. Inducible nitric oxide synthase is expressed in normal human melanocytes but not in melanoma cells in response to tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharide. J Invest Dermatol. 2002;118:1019-25 pubmed
  45. Kiewe P, Jovanovic S, Thiel E, Korfel A. Reversible ageusia after chemotherapy with pegylated liposomal doxorubicin. Ann Pharmacother. 2004;38:1212-4 pubmed
    ..To report a case of reversible ageusia in a patient with multiple myeloma receiving pegylated liposomal doxorubicin...
  46. Schneider K, Keller S, Wolter F, Röglin L, Beil W, Seitz O, et al. Proximicins A, B, and C-antitumor furan analogues of netropsin from the marine actinomycete Verrucosispora induce upregulation of p53 and the cyclin kinase inhibitor p21. Angew Chem Int Ed Engl. 2008;47:3258-61 pubmed publisher
  47. Liu W, Bensdorf K, Proetto M, Abram U, Hagenbach A, Gust R. NHC gold halide complexes derived from 4,5-diarylimidazoles: synthesis, structural analysis, and pharmacological investigations as potential antitumor agents. J Med Chem. 2011;54:8605-15 pubmed publisher
    ..The missing ER binding and the missing correlation of growth inhibition and inactivation of COX enzymes exclude these targets, too. ..
  48. Harnack U, Kellermann U, Pecher G. Yeast-derived beta-(1-3),(1-6)-D-glucan induces up-regulation of CD86 on dectin-1-positive human B-lymphoma cell lines. Anticancer Res. 2011;31:4195-9 pubmed
    ..Yeast-derived beta-glucan lacks cytotoxic effects towards B-lymphoma cells but up-regulation of CD86 suggests maturation of the cells via dectin-1 by the carbohydrate. ..
  49. Luyten A, Sörgel P, Clad A, Gieseking F, Maass Poppenhusen K, Lelle R, et al. Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy Network. J Am Acad Dermatol. 2014;70:644-650 pubmed publisher
    ..When associated cancers and invasive growth are excluded, imiquimod appears to be a useful treatment option for recurrent EMPD and may avoid extensive mutilating surgical treatment. ..
  50. Bahleda R, Grilley Olson J, Govindan R, Barlesi F, Greillier L, Perol M, et al. Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies. Br J Cancer. 2017;116:1505-1512 pubmed publisher
    ..4% for patients with SCLC (n=33), and 33.3% for patients with CDK-related tumour mutations (n=6). Roniciclib demonstrated an acceptable safety profile and moderate DCR in 3 days on/4 days off schedule. ..
  51. Zang C, Wächter M, Liu H, Posch M, Fenner M, Stadelmann C, et al. Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol. 2003;65:107-18 pubmed
    ..Therefore, we conclude that these ligands may possess adjuvant therapeutic potential for patients with glioblastoma. ..
  52. Rhein P, Mitlohner R, Basso G, Gaipa G, Dworzak M, Kirschner Schwabe R, et al. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia. Blood. 2010;115:3763-71 pubmed publisher
    ..Taken together, CD11b expression has considerable implications for prognosis, treatment response monitoring, and MRD detection in childhood PBC-ALL. ..
  53. Lage H, Kellner U. [Resistance to medicinal tumor therapy. Current status]. Pathologe. 2013;34:398-402 pubmed publisher
    ..Therefore, it will be necessary to develop improved diagnostic assays for prediction of individual therapy response. ..
  54. Roblek M, Calin M, Schlesinger M, Stan D, Zeisig R, Simionescu M, et al. Targeted delivery of CCR2 antagonist to activated pulmonary endothelium prevents metastasis. J Control Release. 2015;220:341-347 pubmed publisher
    ..Thus, timely- and spatially-defined inhibition of CCR2 signaling represents a potential therapeutic approach for treatment of metastasis without affecting homeostatic functions. ..
  55. Srock S, Schriever F, Neubauer A, Herold M, Huhn D. Long-term treatment with rituximab is feasible in selected patients with B-CLL: response-adjusted low-dose maintenance treatment with rituximab in patients with relapsed B-CLL, who achieved a partial or minimal response to prior rituximab therapy. Leuk Lymphoma. 2007;48:905-11 pubmed
    ..5 years so far. Long-term toxicity, as determined based on hematological and immunological parameters, was mild. ..
  56. Plockinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab. 2007;21:145-62 pubmed
    ..This is followed by an in-depth description of the use of biotherapy, its results with respect to symptomatic and antiproliferative treatment, as well as its side-effects. ..
  57. Liu H, Zang C, Schefe J, Schwarzlose Schwarck S, Regierer A, Elstner E, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res. 2011;31:2713-22 pubmed
    ..On the basis of these results, we have initiated a phase I/II clinical trial with the combination of carboplatin and RAD001 in patients with metastatic breast cancer. ..
  58. Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F, et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res. 2014;323:131-43 pubmed publisher
    ..This validates the approach to use 3D cell culture screening systems to identify substances that would not be detectable by 2D based screening in otherwise similar culture conditions. ..
  59. Zhong Y, Goltsche K, Cheng L, Xie F, Meng F, Deng C, et al. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials. 2016;84:250-261 pubmed publisher
    ..These results indicate that hyaluronic acid-shelled acid-activatable PTX prodrug micelles have a great potential for targeted chemotherapy of CD44-positive cancers. ..
  60. Heider U, Kaiser M, Mieth M, Lamottke B, Rademacher J, Jakob C, et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol. 2009;82:31-8 pubmed publisher
    ..These data suggest that myeloma cells are the main source of circulating DKK-1 protein and provide a framework for clinical trials on anti-DKK-1 treatment in MM. ..
  61. Braumann C, Ordemann J, Kilian M, Wenger F, Jacobi C. Local and systemic chemotherapy with taurolidine and taurolidine/heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis. 2003;20:387-94 pubmed
    ..Neither the intraperitoneal nor the intravenous application or the combination of the two agents influenced the subcutaneous tumor growth. The substances did not alter the changes of peripheral leukocytes. ..
  62. Stein U, Arlt F, Smith J, Sack U, Herrmann P, Walther W, et al. Intervening in ?-catenin signaling by sulindac inhibits S100A4-dependent colon cancer metastasis. Neoplasia. 2011;13:131-44 pubmed
    ..These results suggest that modulators of ?-catenin signaling such as sulindac offer potential as antimetastatic agents by interdicting S100A4 expression. ..
  63. Liu H, Scholz C, Zang C, Schefe J, Habbel P, Regierer A, et al. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro. Anticancer Res. 2012;32:1627-37 pubmed
    ..Our investigation provides a rationale for the clinical application of metformin within treatment regimens for breast cancer. ..
  64. Lemos C, Sack U, Schmid F, Juneja M, Stein U. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways. Curr Pharm Des. 2013;19:841-63 pubmed
    ..In this review, we summarize the new developments in this field, focusing on the inhibitors that show more promising results for use in colorectal cancer patients. ..
  65. Ott I, Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem. 2007;7:95-110 pubmed
    ..g. including taxanes) are administered. This review covers the latest findings about new platinum complexes in preclinical studies on the use against breast cancer as well as the outcome of the most relevant clinical trials. ..
  66. Mustea A, Sehouli J, Fabjani G, Koensgen D, Mobus V, Braicu E, et al. Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study. Anticancer Res. 2007;27:1527-30 pubmed
    ..Mutations in the kinase domain of the EGFR, exons 19 and 21, are absent or very infrequent in patients with OC. ..
  67. Jing H, Kase J, Dörr J, Milanovic M, Lenze D, Grau M, et al. Opposing roles of NF-?B in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev. 2011;25:2137-46 pubmed publisher
  68. Sehouli J, Runnebaum I, Fotopoulou C, Blohmer U, Belau A, Leber H, et al. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol. 2012;23:2259-64 pubmed publisher
    ..This sequential regime may constitute an alternative option when contraindications for immediate postoperative radiation are present. ..
  69. Stock K, Kumar J, Synowitz M, Petrosino S, Imperatore R, Smith E, et al. Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nat Med. 2012;18:1232-8 pubmed publisher
    ..NPC-mediated tumor suppression can be mimicked in the adult brain by systemic administration of the synthetic vanilloid arvanil, suggesting that TRPV1 agonists have potential as new HGA therapeutics. ..
  70. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280:168-76 pubmed publisher
  71. Danker K, Reutter W, Semini G. Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol. 2010;160:36-47 pubmed publisher
    ..We intend to highlight the potential of glycosidated phospholipids, especially Ino-C2-PAF, as a promising new group of drugs for the treatment of hyperproliferative and migration-based skin diseases. ..
  72. Hopfner M, Maaser K, Theiss A, Lenz M, Sutter A, Kashtan H, et al. Hypericin activated by an incoherent light source has photodynamic effects on esophageal cancer cells. Int J Colorectal Dis. 2003;18:239-47 pubmed
    ..Both the well known clinical safety of hypericin and the lower costs of broad band light sources argue in favor of clinical trials. ..
  73. Mund C, Lyko F. Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays. 2010;32:949-57 pubmed publisher
    ..Future research should be directed toward targeted enzyme inhibition and toward exploring interactions between epigenetic pathways to maximize cancer specificity. ..
  74. Schwarz M, Kreuzer K, Baskaynak G, Dorken B, Le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002;69:254-6 pubmed
    ..Our report confirms another single observation of acute generalized exanthematous pustulosis in chronic myeloid leukemia under imatinib therapy, and confirms that this is a rare but proven adverse effect of imatinib. ..
  75. Budde K, Zonnenberg B, Frost M, Cheung W, Urva S, Brechenmacher T, et al. Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis. Br J Clin Pharmacol. 2016;81:958-70 pubmed publisher
    ..These findings suggest that plasma angiogenic markers may provide an objective measure of patient response to everolimus. ..
  76. Sutter A, Maaser K, Hopfner M, Barthel B, Grabowski P, Faiss S, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer. 2002;102:318-27 pubmed
    ..Our data qualify PBR-specific ligands as innovative proapoptotic and antiproliferative substances. They might prove suitable for the treatment of esophageal cancer. ..
  77. Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, et al. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin an. Cytokine. 2013;61:755-8 pubmed publisher
    ..Further analyses are warranted to allow an implementation of such markers into clinical practice. ..
  78. Rugo H, Hortobagyi G, Yao J, Pavel M, Ravaud A, Franz D, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016;27:519-25 pubmed publisher
    ..22)] and RADIANT-2 [HR, 0.87 (95% CI, 0.61-1.22)] but not in BOLERO-3 [HR, 1.01 (95% CI, 0.75-1.36)]. Stomatitis did not adversely affect PFS, supporting the administration of everolimus in accordance with standard management guidelines. ..
  79. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay P, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20:2805-11 pubmed
    ..Antiemetic treatment with tropisetron or ondansetron could be improved by adjustment for the CYP2D6 genotype; approximately 50 subjects would have to be genotyped to protect one patient from severe emesis. ..
  80. Denecke T, Hildebrandt B, Lehmkuhl L, Peters N, Nicolaou A, Pech M, et al. Fusion imaging using a hybrid SPECT-CT camera improves port perfusion scintigraphy for control of hepatic arterial infusion of chemotherapy in colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2005;32:1003-10 pubmed
    ..In patients receiving HAI, port perfusion scintigraphy by fusion imaging with a hybrid SPECT-CT system provides important information for therapy optimisation and appears to be superior to SPECT alone. ..
  81. Sehouli J, Stengel D, Mustea A, Camara O, Keil E, Elling D, et al. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol. 2008;61:243-50 pubmed
    ..6% (95% CI 41.4-69.1%) of patients. Median progression free and overall survival was 21 and 43 months, respectively. PC-W is feasible; a randomized study is warranted to compare this new regimen with conventional 3-weekly treatment. ..
  82. Abramjuk C, Bueschges M, Schnorr J, Jung K, Staack A, Lein M. Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. Oncol Rep. 2009;22:409-14 pubmed
    ..In contrast to other authors we could not find any anti-proliferative effect, we actually showed that instillation into the rat urinary bladder enhanced tumor growth. ..
  83. Pavel M. [Metastatic neuroendocrine neoplasms. Non-surgical treatment strategies]. Chirurg. 2011;82:612-7 pubmed publisher
    ..This review presents the management of patients with small intestinal and pancreatic NEN with respect to the functionality and tumor grading. The use of novel targeted drug therapy is included in a therapeutic algorithm...
  84. Muallem M, Marnitz S, Richter R, Köhler C, Sehouli J, Arsenic R. ERCC1 expression as a predictive marker of cervical cancer treated with cisplatin-based chemoradiation. Anticancer Res. 2014;34:401-6 pubmed
    ..7% and 90.7%, respectively. The present study did not confirm the correlation of low levels of ERCC1 expression with unfavorable outcomes of patients with locally advanced cervical cancer treated with platin-based radiochemotherapy. ..
  85. Winter A, Sigurdardottir A, DiCara D, Valenti G, Blundell T, Gherardi E. Developing Antagonists for the Met-HGF/SF Protein-Protein Interaction Using a Fragment-Based Approach. Mol Cancer Ther. 2016;15:3-14 pubmed publisher
  86. Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O, et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma. 2006;47:59-63 pubmed
  87. Zang C, Liu H, Bertz J, Possinger K, Koeffler H, Elstner E, et al. Induction of endoplasmic reticulum stress response by TZD18, a novel dual ligand for peroxisome proliferator-activated receptor alpha/gamma, in human breast cancer cells. Mol Cancer Ther. 2009;8:2296-307 pubmed publisher
    ..In summary, TZD18-treatment leads to the activation of endoplasmic reticulum stress response and, subsequently, growth arrest and apoptosis in breast cancer cells. ..
  88. Czabanka M, Parmaksiz G, Bayerl S, Nieminen M, Trachsel E, Menssen H, et al. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. Eur J Cancer. 2011;47:1276-84 pubmed publisher
    ..Microvascular biodistribution is enhanced in anti-angiogenic-therapy resistant tumour vessels. ..
  89. Brose M, Nutting C, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319-28 pubmed publisher
    ..In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer...
  90. Schostak M, Miller K, Schrader M. Hormone therapy for prostate cancer - immediate initiation. Front Radiat Ther Oncol. 2008;41:49-57 pubmed publisher
    ..This management can prevent prostate cancer from migrating to the bones, where treatment becomes extremely difficult and cure or even longterm control of the disease is an exception. ..
  91. Ahmed J, Meinel T, Dunkel M, Murgueitio M, Adams R, Blasse C, et al. CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge. Nucleic Acids Res. 2011;39:D960-7 pubmed publisher
    ..CancerResource addresses the spectrum of research on compound-target interactions in natural sciences as well as in individualized medicine; CancerResource is available at: http://bioinformatics.charite.de/cancerresource/. ..
  92. Chanvillard C, Millward J, Lozano M, Hamann I, Paul F, Zipp F, et al. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis. PLoS ONE. 2012;7:e39625 pubmed publisher
    ..Our data emphasize the complex immunomodulatory role of mitoxantrone, which may account for its benefit in MS. In particular, these results highlight the contribution of NK cells to mitoxantrone efficacy in progressive MS. ..